Romero MS, Godínez TNC, Yescas-Buendía G, Fernández-Carrocera LA, Echániz AMOL, Reyna RER

Language: Spanish
References: 24
Page: 422-429
PDF size: 278.19 Kb.

ABSTRACT

Background. The prevalence of neonatal cholestasis varies from 7–57%. Part of the treatment includes ursodeoxycholic acid (UDCA) and phenobarbital, both with little supporting evidence in the literature.
We undertook this study to compare the effectiveness of phenobarbital vs. UDCA in reducing the direct serum bilirubin levels in patients with cholestasis and weighing from 1 000 to 2 000 g.
Methods. Using a cross-randomized clinical trial, 18 patients were included with 36 treatments. Each subject randomly received one of the two interventions: UDCA (10 mg/kg/day) every 12 h or phenobarbital (3 mg/kg/day, every 24 h for 7 days) continuing with 7 days of wash-out to return to their initial state, and to subsequently receive the other treatment. At the beginning and at the end of the administration of each medication, bilirubin concentrations and hepatic test functions were measured. Central tendency and dispersion measurements were applied according to the type of variable. For hypothesis confirmation, paired t-test was carried out.
Results. The obtained results indicate that with UDCA at a dose of 10 mg/kg/day every 12 h for 7 days, serum bilirubin levels decreased to 2.7 mg/dL (p ‹0.01). Phenobarbital had no effect in reducing bilirubin concentration.
Conclusion. Use of UDCA is recommended at a dose of 10 mg/kg/dose every 12 h (PO) as a coadjuvant in the treatment of neonatal cholestasis.

REFERENCES

1. Peden VH, Witzleben CL, Skelton MA. Total parenteral nutrition. J Pediatr 1971;78:180-181.

2. Balistreri WF. Liver disease in infancy and childhood. En: Schiff ER, Sorrell MF, Madrey WC, eds. Schiff¨s Disease of the Liver. Philadelphia: Lippincott-Raven, 1999; pp. 1357-1512.

3. Worona-Dibner LB, García-Aranda JA. Colestasis neonatal. Bol Med Hosp Infant Mex 2003:60;334-348.

4. Karpen SJ. Update on the etiologies and management of neonatal cholestasis. Clin Perinatol 2002;29:159-180.

5. Suchy FJ. Approach to the infant with cholestasis. En: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver Disease in Children. Philadelphia, PA: Lippincott, Williams and Wilkins, 2001; pp.187-194.

6. Young TE. Manual de drogas neonatológicas. En: Neofax, Editorial Panamericana, 2002.

7. Bernstein J, Chang CH, Brough AJ, Heidelberger KP. Conjugated hyperbilirubinemia in infancy associated with parenteral alimentation. J Pediatr 1997;90:361-367.

8. Coger RH. Hepatic complications of parenteral nutrition. Semin Liver Dis 1983;3:216-224.

9. Moss RL, Das JB, Raffensperger JG. Total parenteral nutrition-associated cholestasis: clinical and histopathologic correlation. J Pediatr Surg 1993;28:1270-1274.

10. Manzanares L, Medina E. Colestasis en el recién nacido y lactante: orientación diagnóstica. Ann Pediatr 2003;58:162-167.

11. Romero-Maldonado S. Incidencia de colestasis neonatal asociada a nutrición parenteral total (Tesis). Instituto Nacional de Perinatología, México D.F., 2002.

12. Gleghorn EE, Merrit RJ, Subramanian N, Ramos A. Phenobarbital does not prevent total parenteral nutrition-associated cholestasis in noninfected neonates. J Parenter Enteral Nutr 1986;10.282-283.

13. Blommer JR, Boyer JL. Phenobarbital effects in cholestatic liver disease. Ann Int Med 1975;82:310-317.

14. Venigalla S, Gourley GR. Neonatal cholestasis. Semin Perinatol 2004:28:348-355.

15. Kapen S. Update on the etiologies and management of neonatal support in patients with chronic cholestasis disease. Ann Pediatr 2003;58:174-180.

16. Pegev RH. Tratamiento de colestasis neonatal en el síndrome de Dubin Johnson. Rev Esp 2004;96:60-73.

17. Chen-Yi C, Po-nen T, Huey-Ling C, Hung-Chen C, Wu-Shun H, Mei-Hwei C. Ursodeoxycholic acid (UDCA) therapy in very low birth weight infants with parenteral nutrition associated cholestasis. J Pediatr 2004;145:317-321.

18. Spagnuolo MI, Iorio R, Vegnete A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996;111:716-719.

19. Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med J 2006;47:147-151.

20. Rodgers BM, Hollenbeck JI, Bonnelly WH, Talbert JL. Intrahepatic cholestasis with parenteral alimentation. Am J Surg 1976;13:14-55.

21. Pereira GR, Sherman MS, DiGiacomo J, Ziegler M, Roth K, Jacobowski D. Hyperalimentation-induced cholestasis and severity in premature infants. Am J Dis Child 1981;135:842-845.

22. Benjamin DR. Hepatobiliary disfunction in infants and children associated with long-term total parenteral nutrition. A clinico-pathologic study. Am J Clin Pathol 1981;76:276-283.

23. Scher H, Bishop WP, McCray PB. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis. Ann Pharmacother 1997;31:1003-1005.

24. Pasha T, Heathcote J, Gabriel S, Cauch Dudek K, Jorgensen R, Therneau T, et al. Cost effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999;29:21-26.